Dr. Reddy's expands APIs in U.K.; Catalent, Parexel partner on trial materials;

>  Dr. Reddy's Laboratories' Custom Pharmaceutical Services business will expand its API manufacturing at its Mirfield, U.K., site to include activated mPEG manufacturing and the development and manufacture of NCE (new chemical entities) APIs. Release

> DSM Pharmaceutical Products, a division of Royal DSM ($DSM), and Almac Group have established a relationship to collaborate on developing and manufacturing APIs. Release

> Karl-Ludwig Kley, chairman of the executive board of Merck KGaA, has been elected president of the German Chemical Industry Association (Verband der Chemischen Industrie e. V. - VCI) Release

> The FDA has sent a warning letter to Akorn of Lake Forest, IL, saying that three hydrochloride ophthalmic solution products it is manufacturing qualify as prescription drugs and giving Akorn 90 days to meet FDA guidelines or stop making them. Letter

And Finally... Catalent Pharma Solutions has formed a new relationship with Parexel to combine Parexel's trial management and logistics services with Catalent's manufacturing and packaging capabilities to build its services in making clinical trial materials. Item

Suggested Articles

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.